Apoquel 5.4 mg Chewable Tablets for Dogs

Dogs:
Very common
(>1 animal / 10 animals treated):
pyoderma, skin lump, papillomaCommon
(1 to 10 animals / 100 animals treated):
lethargy, lipoma, polydipsia, increased
appetite
nausea, vomiting, diarrhoea, anorexia
histiocytoma, fungal skin infection,
pododermatitis
otitis
lymphadenopathy
cystitis
aggression

Revised: December 2025
AN: 03096/2025
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
anaemia, lymphoma, convulsion
Treatment-related clinical pathology changes were restricted to an increase in mean serum
cholesterol and a decrease in mean leukocyte count, however, all mean values remained
within the laboratory reference range. The decrease in mean leukocyte count observed in
oclacitinib-treated dogs was not progressive, and affected all white blood cell counts
(neutrophil, eosinophil and monocyte counts) except lymphocyte counts. Neither of these
clinical pathology changes appeared clinically significant.
Regarding susceptibility to infection and neoplastic conditions, see section 4.5 “Special
precautions for use”.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary
medicinal product. Reports should be sent, preferably via a veterinarian, to either the
marketing authorisation holder or the national competent authority via the national reporting
system. See the package leaflet for respective contact details.